Evidence map›Paper›PMID 38139208›Full record

ArticleInternational journal of molecular sciences2023

Improved Glycaemic Control and Nephroprotective Effects of Empagliflozin and Paricalcitol Co-Therapy in Mice with Type 2 Diabetes Mellitus.

Abdulrahman Mujalli, Wesam F Farrash, Ahmad A Obaid, Anmar A Khan, Riyad A Almaimani, Shakir Idris, Mohamed E Elzubier, Elshiekh Babiker A Khidir, Akhmed Aslam, Faisal Minshawi and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Abdulrahman MujalliDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0002-8630-3963
Wesam F FarrashDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0002-2886-9678
Ahmad A ObaidDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0003-2678-4424
Anmar A KhanDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.
Riyad A AlmaimaniBiochemistry Department, Faculty of Medicine, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0001-7944-2597
Shakir IdrisDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.
Mohamed E ElzubierBiochemistry Department, Faculty of Medicine, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0002-6335-1778
Elshiekh Babiker A KhidirDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0001-5956-9849
Akhmed AslamDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0002-0416-936X
Faisal MinshawiDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0003-4677-9614
Mohammad A AlobaidyDepartment of Anatomy, Faculty of Medicine, Umm AlQura University, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0002-6911-9179
Adel B AlharbiDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0002-9644-1032
Hussain A AlmasmoumDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0003-0542-418X
Mazen GhaithDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.
Khalid AlqethamiDepartment of Laboratory, Al-Noor Specialist Hospital, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0002-2055-8728
Bassem RefaatDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Al Abdeyah, Makkah P.O. Box 7607, Saudi Arabia.ORCID 0000-0003-4267-1016
Umm al-Qura University · SASaad Specialist Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, we measured the antidiabetic and nephroprotective effects of the sodium-glucose cotransporter-2 inhibitor (empagliflozin; SGLT2i) and synthetic active vitamin D (paricalcitol; Pcal) mono- and co-therapy against diabetic nephropathy (DN). Fifty mice were assigned into negative (NC) and positive (PC) control, SGLT2i, Pcal, and SGLT2i+Pcal groups. Following establishment of DN, SGLT2i (5.1 mg/kg/day) and/or Pcal (0.5 µg/kg/day) were used in the designated groups (5 times/week/day). DN was affirmed in the PC group by hyperglycaemia, dyslipidaemia, polyuria, proteinuria, elevated urine protein/creatinine ratio, and abnormal renal biochemical parameters. Renal SREBP-1 lipogenic molecule, adipokines (leptin/resistin), pro-oxidant (MDA/H

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesDyslipidemiasHyperglycemiaSodium-Glucose Transporter 2 InhibitorsAnimalsAnti-Inflammatory AgentsAntioxidantsBenzhydryl CompoundsErgocalciferolsGlucosidesGlycemic ControlHydrogen PeroxideInflammationMiceAnti-Inflammatory AgentsAntioxidantsBenzhydryl CompoundsempagliflozinErgocalciferolsGlucosidesHydrogen PeroxideparicalcitolSodium-Glucose Transporter 2 InhibitorsadipokinesINOSKIM-1NGALSGLT2 inhibitorTGF-βvitamin D

Identifiers

PMID38139208
PMCPMC10743534
OpenAlexW4389623303

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.